Abstract: Objective To explore the clinical efficacy of different forms of paclitaxel combined with cisplatin in the treatment of advanced non-small cell lung cancer（NSCLC）. Methods From January 2014 to January 2016，90 patients with advanced NSCLC treated in our hospital were assigned to 3 groups： 31 cases in paclitaxel group treated with paclitaxel combined with cisplatin， 27 cases in liposome paclitaxel group treated with liposome paclitaxel combined with cisplatin and 32 cases in albumin bound paclitaxel group treated with albumin bound paclitaxel combined with cisplatin. Response to chemotherapy was assessed by RECIST criteria 1.1 and toxicity was evaluated according to National Cancer Institute Common Toxicity Criteria 4.0. The clinical follow-up data from chemotherapy were investigated for comparison of median progression free survival（PFS）among different groups. Results All patients were available for evaluation. The effective rates were 16.1％， 18.5％ and 21.9％ and disease control rates were 87.1％， 92.6％ and 93.8％ in paclitaxel group， liposome paclitaxel group and albumin bound paclitaxel group，respectively. There were no significant difference among three groups（P＞0.05）. The median PFS of paclitaxel group， liposomal paclitaxel group and albumin bound paclitaxel group were 9.0， 10.0 and 12.0 months，and the difference was not statistically significant （P＞0.05）. The total incidence rates of nausea and vomiting were 44.4％ and 34.4％ and total incidence rates of muscle／joint pain were 18. 5％ and 12.5％ in liposomal paclitaxel group and albumin bound paclitaxel group，significantly lower than those in the paclitaxel group（P＜0.05）. ConclusionThere were similar efficacies in NSCLC patients receiving different forms of paclitaxel plus cisplatin. The toxicity and side effects of liposomal paclitaxel and albumin bound paclitaxel are relatively mild，may serving as a treatment candidate for patients with a larger age and poor general condition.